Gossamer Bio Inc. (GOSS) faces a major clinical catalyst this month as data for its lead drug candidate, Seralutinib, approaches - a potential event that could significantly impact the company's share price.
Seralutinib is an investigational, inhaled, small molecule inhibitor of platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R) and mast/stem cell growth factor receptor kit (c-KIT). It is designed to target the mechanisms that underlie pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease and to be delivered to the site of disease via a dry powder inhaler.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.